|
1
|
Schiller JH, Gandara DR, Goss GD and Vokes
EE: Non-small-cell lung cancer: Then and now. J Clin Oncol.
31:981–983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zou Z, Anisowicz A, Hendrix MJ, Thor A,
Neveu M, Sheng S, Rafidi K, Seftor E and Sager R: Maspin, a serpin
with tumor-suppressing activity in human mammary epithelial cells.
Science. 263:526–529. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zou Z, Zhang W, Young D, Gleave MG, Rennie
P, Connell T, Connelly R, Moul J, Srivastava S and Sesterhenn I:
Maspin expression profile in human prostate cancer (CaP) and in
vitro induction of Maspin expression by androgen ablation. Clin
Cancer Res. 8:1172–1177. 2002.PubMed/NCBI
|
|
4
|
Katakura H, Takenaka K, Nakagawa M, Sonobe
M, Adachi M, Ito S, Wada H and Tanaka F: Maspin gene expression is
a significant prognostic factor in resected non-small cell lung
cancer (NSCLC). Maspin in NSCLC. Lung Cancer. 51:323–328. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lonardo F, Li X, Kaplun A, Soubani A,
Sethi S, Gadgeel S and Sheng S: The natural tumor suppressor
protein maspin and potential application in non small cell lung
cancer. Curr Pharm Des. 16:1877–1881. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mohsin SK, Zhang M, Clark GM and Craig
Allred D: Maspin expression in invasive breast cancer: Association
with other prognostic factors. J Pathol. 199:432–435. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Joensuu KM, Leidenius MH, Andersson LC and
Heikkilä PS: High expression of maspin is associated with early
tumor relapse in breast cancer. Hum Pathol. 40:1143–1151. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maass N, Hojo T, Ueding M, Lüttges J,
Klöppel G, Jonat W and Nagasaki K: Expression of the tumor
suppressor gene Maspin in human pancreatic cancers. Clin Cancer
Res. 7:812–817. 2001.PubMed/NCBI
|
|
9
|
Sood AK, Fletcher MS, Gruman LM, Coffin
JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA and Hendrix
MJ: The paradoxical expression of maspin in ovarian carcinoma. Clin
Cancer Res. 8:2924–2932. 2002.PubMed/NCBI
|
|
10
|
Baek JY, Yeo HY, Chang HJ, Kim KH, Kim SY,
Park JW, Park SC, Choi HS, Kim DY and Oh JH: Serpin B5 is a
CEA-interacting biomarker for colorectal cancer. Int J Cancer.
134:1595–1604. 2014. View Article : Google Scholar
|
|
11
|
Snoeren N, Emmink BL, Koerkamp MJ, van
Hooff SR, Goos JA, van Houdt WJ, de Wit M, Prins AM, Piersma SR,
Pham TV, et al: Maspin is a marker for early recurrence in primary
stage III and IV colorectal cancer. Br J Cancer. 109:1636–1647.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takagi Y, Matsuoka Y, Shiomi T, Nosaka K,
Takeda C, Haruki T, Araki K, Taniguchi Y, Nakamura H and Umekita Y:
Cytoplasmic maspin expression is a predictor of poor prognosis in
patients with lung adenocarcinoma measuring <3 cm.
Histopathology. 66:732–739. 2014. View Article : Google Scholar
|
|
13
|
Narayan M and Twining S: Focus on
molecules: Maspin. Exp Eye Res. 90:2–3. 2010. View Article : Google Scholar
|
|
14
|
Teoh SS, Vieusseux J, Prakash M, Berkowicz
S, Luu J, Bird CH, Law RH, Rosado C, Price JT, Whisstock JC, et al:
Maspin is not required for embryonic development or tumour
suppression. Nat Commun. 5(3164)2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, Chen D, Yin S, Meng Y, Yang H,
Landis-Piwowar KR, Li Y, Sarkar FH, Reddy GP, Dou QP, et al: Maspin
augments proteasome inhibitor-induced apoptosis in prostate cancer
cells. J Cell Physiol. 212:298–306. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tahmatzopoulos A, Sheng S and Kyprianou N:
Maspin sensitizes prostate cancer cells to doxazosin-induced
apoptosis. Oncogene. 24:5375–5383. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu J, Yin S, Reddy N, Spencer C and Sheng
S: Bax mediates the apoptosis-sensitizing effect of maspin. Cancer
Res. 64:1703–1711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Latha K, Zhang W, Cella N, Shi HY and
Zhang M: Maspin mediates increased tumor cell apoptosis upon
induction of the mitochondrial permeability transition. Mol Cell
Biol. 25:1737–1748. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McKenzie S, Sakamoto S and Kyprianou N:
Maspin modulates prostate cancer cell apoptotic and angiogenic
response to hypoxia via targeting AKT. Oncogene. 27:7171–7179.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sheng S, Carey J, Seftor EA, Dias L,
Hendrix MJ and Sager R: Maspin acts at the cell membrane to inhibit
invasion and motility of mammary and prostatic cancer cells. Proc
Natl Acad Sci USA. 93:11669–11674. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cher ML, Biliran HR Jr, Bhagat S, Meng Y,
Che M, Lockett J, Abrams J, Fridman R, Zachareas M and Sheng S:
Maspin expression inhibits osteolysis, tumor growth, and
angiogenesis in a model of prostate cancer bone metastasis. Proc
Natl Acad Sci USA. 100:7847–7852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen EI and Yates JR III: Maspin and tumor
metastasis. IUBMB Life. 58:25–29. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ravenhill L, Wagstaff L, Edwards DR, Ellis
V and Bass R: G-helix of maspin mediates effects on cell migration
and adhesion. J Biol Chem. 285:36285–36292. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bircan A, Bircan S, Kapucuoglu N, Songur
N, Ozturk O and Akkaya A: Maspin, VEGF and p53 expression in small
biopsies of primary advanced lung cancer and relationship with
clinico-pathologic parameters. Pathol Oncol Res. 16:553–561. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Berardi R, Santinelli A, Onofri A,
Brunelli A, Pierantoni C, Pisa E, Pagliacci A, Stramazzotti D,
Zuccatosta L, Mazzanti P, et al: Maspin expression is a favorable
prognostic factor in non-small cell lung cancer. Anal Quant Cytol
Histol. 34:72–78. 2012.PubMed/NCBI
|
|
26
|
Frey A, Soubani AO, Adam AK, Sheng S, Pass
HI and Lonardo F: Nuclear, compared with combined nuclear and
cytoplasmic expression of maspin, is linked in lung adenocarcinoma
to reduced VEGF-A levels and in Stage I, improved survival.
Histopathology. 54:590–597. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim S, Han J, Kim J and Park C: Maspin
expression is transactivated by p63 and is critical for the
modulation of lung cancer progression. Cancer Res. 64:6900–6905.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Choy B, Findeis-Hosey JJ, Li F, McMahon
LA, Yang Q and Xu H: High frequency of coexpression of maspin with
p63 and p53 in squamous cell carcinoma but not in adenocarcinoma of
the lung. Int J Clin Exp Pathol. 6:2542–2547. 2013.PubMed/NCBI
|
|
29
|
Beltran AS and Blancafort P: Reactivation
of MASPIN in non-small cell lung carcinoma (NSCLC) cells by
artificial transcription factors (ATFs). Epigenetics. 6:224–235.
2011. View Article : Google Scholar
|
|
30
|
Berardi R, Morgese F, Onofri A, Mazzanti
P, Pistelli M, Ballatore Z, Savini A, De Lisa M, Caramanti M,
Rinaldi S, et al: Role of maspin in cancer. Clin Transl Med.
2(8)2013.PubMed/NCBI
|
|
31
|
Takanami I, Abiko T and Koizumi S:
Expression of maspin in non-small-cell lung cancer: Correlation
with clinical features. Clin Lung Cancer. 9:361–366. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ali-Labib R, Louka ML, Galal IH and Tarek
M: Evaluation of matrix metalloproteinase-2 in lung cancer.
Proteomics Clin Appl. 8:251–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Denk AE, Bettstetter M, Wild PJ, Hoek K,
Bataille F, Dietmaier W and Bosserhoff AK: Loss of maspin
expression contributes to a more invasive potential in malignant
melanoma. Pigment Cell Res. 20:112–119. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bernardo MM, Meng Y, Lockett J, Dyson G,
Dombkowski A, Kaplun A, Li X, Yin S, Dzinic S, Olive M, et al:
Maspin reprograms the gene expression profile of prostate carcinoma
cells for differentiation. Genes Cancer. 2:1009–1022. 2011.
View Article : Google Scholar
|
|
35
|
Yin S, Lockett J, Meng Y, Biliran H Jr,
Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, et al: Maspin
retards cell detachment via a novel interaction with the
urokinase-type plasminogen activator/urokinase-type plasminogen
activator receptor system. Cancer Res. 66:4173–4181. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Endsley MP, Hu Y, Deng Y, He X, Warejcka
DJ, Twining SS, Gonias SL and Zhang M: Maspin, the molecular bridge
between the plasminogen activator system and beta1 integrin that
facilitates cell adhesion. J Biol Chem. 286:24599–24607. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang XM, Li J, Yan MX, Liu L, Jia DS, Geng
Q, Lin HC, He XH, Li JJ and Yao M: Integrative analyses identify
osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for
lung cancer. PLoS One. 8:e557142013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jahangiri A, Aghi MK and Carbonell WS: β1
integrin: Critical path to antiangiogenic therapy resistance and
beyond. Cancer Res. 74:3–7. 2014. View Article : Google Scholar :
|
|
39
|
Kanda R, Kawahara A, Watari K, Murakami Y,
Sonoda K, Maeda M, Fujita H, Kage M, Uramoto H, Costa C, et al:
Erlotinib resistance in lung cancer cells mediated by integrin
β1/Src/Akt-driven bypass signaling. Cancer Res. 73:6243–6253. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wojtalla A and Arcaro A: Targeting
phosphoinositide 3-kinase signalling in lung cancer. Crit Rev Oncol
Hematol. 80:278–290. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nam E and Park C: Maspin suppresses
survival of lung cancer cells through modulation of Akt pathway.
Cancer Res Treat. 42:42–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bentley C, Jurinka SS, Kljavin NM,
Vartanian S, Ramani SR, Gonzalez LC, Yu K, Modrusan Z, Du P,
Bourgon R, et al: A requirement for wild-type Ras isoforms in
mutant KRas-driven signalling and transformation. Biochem J.
452:313–320. 2013. View Article : Google Scholar : PubMed/NCBI
|
